BETAMETHASONE VALERATE (betamethasone valerate) by Sandoz is clinical pharmacology: topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. First approved in 1983.
Drug data last refreshed 7h ago · AI intelligence enriched 1mo ago
Betamethasone valerate is a mid-potency topical corticosteroid lotion that reduces inflammation, itching, and vasodilation in dermatological conditions. It works by suppressing inflammatory mediators and immune responses in the skin, though the exact mechanism remains incompletely understood. The drug is absorbed through intact and inflamed skin, metabolized hepatically, and excreted renally.
This legacy product is approaching loss of exclusivity with modest Part D utilization (123K claims), signaling a mature, cost-focused commercial environment with limited team expansion opportunities.
CLINICAL PHARMACOLOGY: Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on BETAMETHASONE VALERATE at Sandoz? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on betamethasone valerate offers limited career growth due to its LOE-approaching status and modest commercial footprint ($4M Part D spending). Roles emphasize brand defense, managed care negotiations, and operational efficiency rather than market expansion or innovation.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo